(Q34690786)

4 August 2017

1 reference

title

Pharmacology of insulin detemir (English)

1 reference

4 August 2017

1 reference

1 reference

1 reference

Peter Kurtzhals

1

1 reference

4 August 2017

1 August 2007

1 reference

Endocrinology and Metabolism Clinics of North America

4 August 2017

1 reference

4 August 2017

36 Suppl 1

1 reference

4 August 2017

14-20

1 reference

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

1 reference

7 January 2021

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Role of zinc in insulin biosynthesis. Some possible zinc-insulin interactions in the pancreatic B-cell

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Insulin Detemir Is Characterized by a Consistent Pharmacokinetic Profile Across Age-Groups in Children, Adolescents, and Adults With Type 1 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980004-1

7 January 2021

10.1016/S0889-8529(07)80004-1

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

17881328